RxDoctor Payments Data

Terrence Doherty, MD

Ophthalmology · Goodlettsville, TNNPI 1144255324

Payments from drug & device makers

$3,960in general payments, 2019–2025

Across 100 payments — averaging $39.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$816
  • Lensar, Inc.$655
  • Johnson & Johnson Surgical Vision, Inc.$472
  • Glaukos Corporation$354
  • Biotissue Holdings Inc.$315
  • Bausch & Lomb Americas Inc.$303
  • plus $1K from 16 others

What the payments were for

  • Food & beverage$3,960100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,960 in reported general payments places this provider in the 75th percentile of 323 ophthalmology providers in Tennessee.

See all ophthalmology providers in Tennessee

Medicare billing

Part B allowed, 2024
$532,985
Medicare patients
1,029
Services billed
3,109

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost50$28,631
RocklatanNetarsudil Mesylat/Latanoprost40$24,270
CombiganBrimonidine Tartrate/Timolol32$12,291
MieboPerfluorohexyloctane/Pf13$9,456
RhopressaNetarsudil Mesylate13$7,371
Prednisolone Acetate99$4,278
Bromfenac Sodium31$4,242
Latanoprost229$3,791
SimbrinzaBrinzolamide/Brimonidine Tart11$3,681
Travoprost16$3,490
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol23$2,782
Brimonidine Tartrate61$1,432
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat62$1,246
Loteprednol Etabonate11$985
MoxifloxacinMoxifloxacin Hcl18$757

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Combigan$816$40,92282 claims
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$132$31,64153 claims
Bausch & Lomb Americas Inc.Miebo$303$9,45613 claims
AlconSimbrinza$164$3,68111 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$141$98511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 323 ophthalmology providers in Tennessee.

Other ophthalmology in Goodlettsville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →